medigraphic.com

2013, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2013; 80 (1)

Aspectos farmacocinéticos de bevacizumab

Montes-Vera MR, Garrido-Acosta O, Anguiano-Robledo L, Sánchez-Navarrete J, Pérez-Cruz E, Rodríguez-Wong U, Cruz-Rico J, Ruiz-Pérez NJ

Language: Spanish
References: 15
Page: 73-78
PDF size: 273.84 Kb.


ABSTRACT

Angiogenesis is a process that involves the growth of new blood vessels from pre-existing vasculature. Vascular endothelial growth factor (VEGF) is the key signal used to promote growth of blood vessels. Bevacizumab is a humanized monoclonal antibody that inhibits the angiogenesis process. This review has the purpose to expose some pharmaceutical aspects of bevacizumab.


REFERENCES

  1. Lauro S, Gomez G, Margarita L, Martínez F, Valeria Alcántara A, Rocío Ortiz L, Martínez RT, et al. Population based prostate cáncer screeninng in north Mexico reveals a high prevalenece of aggressive tumors in detected cases. BMC Cancer 2009.

  2. Martínez-Esquerro y Herrera. Angiogénesis: VEGF/VEGFRS como blancos terapéuticos en el tratamiento contra el cáncer. Cancerología 2006; 83-96.

  3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.

  4. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011; 31: 161-8. [PubMed].

  5. Pieh C, Agostini H, Buschbeck C, Krüger M, Schulte-Mönting J, Zirrgiebel U, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008; 92: 689-93 [PubMed].

  6. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695.e1-15 [PubMed].

  7. Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 2010; 51: 3701-8 [PubMed].

  8. Hård AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr 2011; 100(12): 1523-7.

  9. Yang-Min Ning, Gulley JL, Arlen PM, Woo S, Seth M. J Clin Oncol 2010; 28(12).

  10. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochemical and Biophysical. Research Communications 2005; 333: 328-35.

  11. Rusovici R, Sakhalkar M, Chalam KV. Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells. Molecular Vision Biology and Genetics in Vision Research. Mol Vis 2011; 17: 3339-46 [PubMed].

  12. Österlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P. Hypertension and overall survival in metastatic colorectal cancer patients treated withbevacizumab-containing chemotherapy. Br J Cancer 2011; 104(4): 599-604 [Epub 2011 Feb 8].

  13. Cross SN, Ratner E, Rutherford TJ, Shwartz PE, Norwitz ER. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol 2012; 5(1): 2-8.

  14. Disponible en: http://www.cellsignal.com/reference/pathway/ Angiogenesis.html

  15. Disponible en: http://www.cancer.gov/espanol/cancer/entendiendo/ angiogenesis/page8search Communications 2005; 333: 328-35.




2020     |     www.medigraphic.com